{
  "document_category": "legal-advice",
  "docId": "legal-advice_72",
  "chunk_index": 9,
  "chunk_text": "-----------------------------------------------------------Thus, the pleadings were joined on the issues of infringement and validity. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------32 none of the claims included in the lawsuits filed against Corporation X,\nand none of Corporation X’s counterclaims, arose from a cause of action other than the\n31 Corporation X had not commercialized the products the subject of the ANDAs in the United States; it\nhad merely filed ANDAs with paragraph IV certifications. 32 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 36 filing of the ANDA pursuant to 35 U.S.C. § 271(e)(2).33 Corporation X’s ANDAs, like all\nANDAs, are assets that can be transferred on a stand-alone basis from one ANDA\nholder to another ANDA holder.34 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Based on the facts and circumstances of this case it is clear that the infringement\nlitigation originated from Corporation X’s actions to obtain assets, FDA-approved\nANDAs, which can be sold or used in its trade or business until such time, if ever, the\nFDA withdraws its approval of the ANDAs.35 Approval can be withdrawn if the ANDA\nholder fails to comply with the requirements for keeping the ANDA effective or if, for\nexample, there are adverse reactions to the generic product that would cause the FDA\nto withdraw its approval. See Addendum A, last 3 pages (addressing requirements\nimposed by statute and regulation on an ANDA holder). Accordingly, the character of\nthe claims is capital since all claims are proximately related to, and have a direct nexus 33 If the claims in the litigation pleading were not all the same, each claim would need to be considered\nseparately, applying the origin of the claim test on a claim-by-claim basis. See Dye v. United States. 121\nF.3d 1399, 1406 (10th Cir. 1997) (“Where, as here, the litigation involves more than one claim, “the origin\n[of the claim] test must be applied separately to each part.\" ) The Dye Court noted that different appellate\ncourts have different positions on how attorney fees should be allocated among claims. 121 F.3d at\n1410. The Dye Court contrasted the Federal Circuit position with the 9th Circuit stating that in Baylin v.\nUnited States, 43 F.3d 1451, 1453 (Fed.Cir.1995), the Federal Circuit allocated “legal expenditures . . .\naccording to the approximate proportion of the lawyers' efforts attributable to the pursuit of each claim.” The Ninth circuit “by contrast, has rejected an approach similar to that of the Baylin court, ‘because it\nignores the contingent fee portion of the taxpayers' contract with their lawyers, and allocates fees only on\nthe basis of the hourly rate portion of the contract.’ Leonard v. Commissioner, 94 F.3d 523, 526 (9th\nCir.1996).” Thus, if allocations of the fees were necessary, the current position of the relevant circuit\ncourts would need to be considered in the allocation. 34 “An applicant may transfer ownership of its application. At the time of transfer the new and former\nowners are required to submit information to the Food and Drug Administration . . . . ” 21 C.F.R .\n§ 314.72(a).\n35"
}